SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DPRLA who wrote (48)9/21/1997 9:11:00 PM
From: John Zwiener   of 178
 
Dave, npth seems to be good. Data indicates it's better than a human screener. We well see if the FDA agrees.

Their competitor is neuromedical/papnet. I think npth is better. The ideal would be both put together, but npth recently bought a company that I think is supposed to display the images that the instrument picked up. With papnet, a screener/human has to make the call on the image displayed on a screen. Npth's instrument makes the call, subject of course to human confirmation. The advantage of npth is that most pap smears are negative/no dyplasia and would not have to be routinely screened after the instrument called it (probably a small percentage of the negative slides would be screened by cytotechs for quality control). In summary, the npth instrument would reduce the workload a lot more than papnet IMHO. Plus it looks like it will soon do the other stuff that papnet does.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News